A hybrid cross-sectional and prospective study to assess patient characteristics, disease burden, disease control, phenotypes, endotypes, and outcomes in a real-world setting in patients with asthma (AIRITY)

未提供0 个研究点目标入组 3,100 人开始时间: 待定

适应症

试验速览

暂无简介。

•Age 6 years and older at the time of signing the consent
•Physician diagnosis of asthma for at least 12 months
•Existing treatment with low, medium, or high dose ICS and other asthma controllers as reflected in GINA steps 2 to 5
•Participant or legally authorized representative (where applicable) has provided consent
•Age 18 years and older at the time of signing the consent
•Physician diagnosis of asthma for at least 12 months
•Existing treatment with low or medium dose ICS and other asthma controllers as reflected in GINA steps 2 to 4
•Participant or legally authorized representative (where applicable) has provided consent
•Participants must meet the criteria for at least one of the cohorts below
•Asthma Control Cohort
•1 ACQ-5 greater than 1.5
•2 ACQ-5 less than 1.5
•Type 2 Biomarker Cohort
•3 FeNO greater than or equal to 35 ppb and blood eosinophils greater than or equal to 300 cells per microliter
•4 FeNO less than 35 ppb and blood eosinophils less than 300 cells per microliter

•Current diagnosis of chronic obstructive pulmonary disease or congestive heart failure.
•Participants with moderate/severe cognitive impairment.
•Participants with moderate/severe cardiac disease.
•Participants on immunosuppressive medication for a chronic condition.
•Participation in other interventional and non-interventional clinical study (currently or in the past 3 months).

发起方

未提供